Chicago Equity Partners’s Anika Therapeutics ANIK Stock Holding History

Chicago Equity Partners’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-10,505	Closed	-$577K	–	862
2019 Q3	$577K	Sell	10,505 -790	-7%	-$40.6K	0.03%	650
2019 Q2	$459K	Buy	+11,295	New	+$412K	0.02%	717
2016 Q4	–	Sell	-6,150	Closed	-$294K	–	714
2016 Q3	$294K	Buy	+6,150	New	+$304K	0.01%	646
2014 Q3	–	Sell	-5,375	Closed	-$249K	–	449
2014 Q2	$249K	Sell	5,375 -1,200	-18%	-$53.4K	0.01%	387
2014 Q1	$270K	Buy	+6,575	New	+$244K	0.01%	394

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Chicago Equity Partners's ANIK Position: Q4 2019 in Review

Chicago Equity Partners sold out of Anika Therapeutics (ANIK) in Q4 2019, closing a stake of 10,505 shares — an estimated $577K sold.

Chicago Equity Partners first reported a position in ANIK in Q1 2014 and held it in 5 quarters. The position peaked at $577K in Q3 2019. 191 funds tracked by Wall St. Rank hold ANIK as of Q4 2019.

Chicago Equity Partners reported no remaining Anika Therapeutics position as of Q4 2019 after selling out during the quarter.
Chicago Equity Partners sold 10,505 Anika Therapeutics shares in Q4 2019, an estimated $577K.
Chicago Equity Partners first reported a position in Anika Therapeutics in Q1 2014 and held it in 5 quarters.
Chicago Equity Partners's Anika Therapeutics position peaked at $577K in Q3 2019.
191 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2019.

Based on Chicago Equity Partners's 13F filing for Q4 2019, filed 10 Feb 2020.